Calton & Associates’s Quest Diagnostics DGX Stock Holding History

Calton & Associates’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-335	Closed	-$34K	–	547
2017 Q4	$34K	Buy	+335	New	+$31.8K	0.01%	776

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Calton & Associates's DGX Position: Q1 2018 in Review

Calton & Associates sold out of Quest Diagnostics (DGX) in Q1 2018, closing a stake of 335 shares — an estimated $34K sold.

Calton & Associates first reported a position in DGX in Q4 2017 and held it in 1 quarter. The position peaked at $34K in Q4 2017. 652 funds tracked by Wall St. Rank hold DGX as of Q1 2018.

Calton & Associates reported no remaining Quest Diagnostics position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 335 Quest Diagnostics shares in Q1 2018, an estimated $34K.
Calton & Associates first reported a position in Quest Diagnostics in Q4 2017 and held it in 1 quarter.
Calton & Associates's Quest Diagnostics position peaked at $34K in Q4 2017.
652 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.